Graft Polymer (UK) - Patent Filings

Solvonis Therapeutics

11/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240711:nRSK9513Va&default-theme=true

RNS Number : 9513V  Graft Polymer (UK) PLC  11 July 2024

 

11 July 2024

Graft Polymer (UK) Plc

("Graft Polymer" or the "Company")

Filing of two new provisional patents applications in the US and operational
review update

Graft Polymer (UK) Plc (LON: GPL), an innovative biopolymer drug delivery
systems development company, is pleased to announce the filing of two new
provisional utility patent applications with the United States Patent and
Trademark Office (the "USPTO"). These provisional patent applications pertain
to the treatment of substance use disorders ("SUDs") and mental health
disorders using depot drug delivery systems ("DDDS").

Provisional patent applications

SUDs

The first provisional patent application, titled "Compositions and Methods for
Treating Substance Use Disorders (SUDs) Using Depot Drug Delivery Systems
(DDDS)", addresses the use of DDDS to reduce side effects and enhance
effectiveness of therapeutics used to treat SUDs. Many such therapeutics
require frequent dosing via traditional routes of administration, and
controlling and extending drug release, such as using biopolymer based depot
delivery systems, can potentially increase patient compliance and potentially
improve outcomes.

Mental health disorders

The second provisional patent application, titled "Compositions and Methods
for Treating Mental Health Disorders (MHDS) Using Depot Drug Delivery Systems
(DDDS)", also focuses on the use of DDDS to reduce side effects and enhance
effectiveness of therapeutics, in particular those used in treating mental
health disorders such as Generalized Anxiety Disorder ("GAD"), Major
Depressive Disorder ("MDD") and Post-Traumatic Stress Disorder ("PTSD").
Similar to treatments for SUDs, current formulations of these therapeutics
often are limited in their effectiveness and have increased side effects as a
result of gastric and hepatic degradation of the API, drawbacks which are
eliminated by the use of biopolymer based depot delivery systems, such as for
controlled subcutaneous release.

Strategic significance

These patent applications aim to leverage the Company's biopolymer expertise
to address significant unmet medical needs in addiction and mental health
therapy, particularly in the US market. They represents continued progress in
developing the Company's intellectual property ("IP") portfolio. They also
signify further progress in the Company's strategic focus on the healthcare
industry, following the disposal of its industrial plastic manufacturing unit,
Graft Polymer D.O.O. (which was announced on 3 May 2024), and the successful
completion of the Company's recent fundraise

Operational review update

 

On 6 June 2024, the Company announced an update on the progress of its
operational review, disclosing that the Board was evaluating a shortlist of
five entities for potential future commercial collaboration in the Company's
area of operation. This operational review is nearing completion and the
Company looks forward to providing further details in the near term.

Anthony Tennyson, CEO, commented:  "We are pleased to announce the filing of
these two new provisional patent applications, which marks another step
forward in our work to leverage the Company's biopolymer expertise for the
potential treatment of substance abuse and mental health disorders. Our
strategic focus on healthcare, underscored by these applications and our
recent corporate actions, demonstrates our commitment to innovation and growth
in this vital sector."

Enquiries

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director, Email:
anthonytennyson@graftpolymer.com

Yifat Steuer, CFO and Executive Director ,  Email: yifat@graftpolymer.com

Allenby Capital (Broker)

Nick Naylor / Liz Kirchner (Corporate Finance)

Guy McDougall (Sales)

+44 (0) 20 3328 5656

About Graft Polymer (UK) Plc

 

Graft Polymer (UK) Plc (LON: GPL) is an innovative developer of biopolymer
drug delivery systems dedicated to assisting biopharmaceutical companies in
enhancing the effectiveness of their therapeutics. Our proprietary patented
platform, a bioabsorbable self-nanoemulsifying drug delivery system
("SNEDDS"), represents a cutting-edge solution in drug delivery technology. By
integrating active pharmaceutical ingredients ("APIs") into our novel,
patented delivery systems, we enable clients to improve the bioavailability,
pharmacokinetics, and stability of their therapeutics.

 

www.graftpolymer.com (http://www.graftpolymer.com) | LinkedIn
(http://www.linkedin.com/company/graft-polymer-uk-plc)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAPQKKBQDBKBOOD